Is Adial Pharmaceuticals Inc (ADIL) overvalued? · $6.0M cap
Adial Pharmaceuticals Inc (ADIL) is a biotechnology company listed on NASDAQ.
This page asks whether Adial Pharmaceuticals Inc (ADIL) looks expensive on cached numbers — not a short thesis.
No cached income statement for ADIL, so there is no earnings base to call rich or cheap.
ADIL currently screens at market cap $6.0M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ADIL 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ADIL stock page for the full model, not this heading.
Not investment advice.